Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

16.73 -0.07 (-0.42%)
Streaming Delayed Price Updated: 3:55 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
35 36 Next >
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Stock Shows Improved Technical Strength ↗
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73. 
Via Investor's Business Daily
News headline image
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst ↗
Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming. 
Via Investor's Business Daily
News headline image
Sarepta Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
A Preview Of Sarepta Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
2 Biotech Stocks to Buy Hand Over Fist in April ↗
These drugmakers have made important moves over the past year. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback ↗
The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy. 
Via Investor's Business Daily
News headline image
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? ↗
The threat is still emerging, but it could be significant. 
Via The Motley Fool
News headline image
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO ↗
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients. 
Via Benzinga
News headline image
Got $1,000? Buy These Hot Growth Stocks Before They Take Off. ↗
These stocks haven't been able to get much traction lately, even though they clearly deserve to now. 
Via The Motley Fool
News headline image
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst ↗
The upcoming regulatory decision on its latest drug could be big. 
Via The Motley Fool
News headline image
Sarepta Therapeutics to Present at Upcoming Investor Conferences
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript ↗
SRPT earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Is It Too Late to Buy Sarepta Therapeutics Stock? ↗
The company's hyperfocus on its core area could continue to be highly lucrative. 
Via The Motley Fool
News headline image
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices ↗
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs. 
Via Benzinga
News headline image
Earnings Scheduled For February 28, 2024 ↗
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
Via Benzinga
News headline image
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight ↗
Sarepta's Elevidys efficacy supplement accepted for Duchenne muscular dystrophy treatment expansion, potential $1 billion yearly opportunity. FDA review goal: June 21, 2024. 
Via Benzinga
News headline image
Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quarter. 
Via Benzinga
News headline image
Why Sarepta Therapeutics Stock Is Soaring Today ↗
The biotech just scored a big FDA win with an even bigger one potentially coming by June. 
Via The Motley Fool
News headline image
Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.